Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 57.37

+0.9%

Dec 8 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (9463)	11/12/2003 8:39:22 AM
From: NeuroInvestment	Read Replies (1) of 52153

Actually (and Erik, this has only very recently come to my attention), the Servier situation turns out to be a bit more complicated than that. Cortex's partnership with Servier guaranteed them that they would receive the same royalties on a Servier compound as a Cortex compound. But I believe that this may only apply to compounds developed by Servier during the term of the partnership, and I think S18986 was already in development prior to the agreement--I guess neither company took it seriously at the time, and assumed they'd be going forward with a later compound. Which would mean it may not fall under the partnership license, and terms for its commercialization would have to be negotiated now. That would make things all the more interesting. Harry NeuroInvestment

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next